Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Ipsen
Yale University
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Seagen Inc.
National Cancer Institute (NCI)
Baylor College of Medicine
Astellas Pharma Inc
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Hoffmann-La Roche
Bristol-Myers Squibb
Leap Therapeutics, Inc.
Bristol-Myers Squibb
NuCana plc
Institut Bergonié
Bristol-Myers Squibb
BeiGene
Gilead Sciences
Mayo Clinic
AIDS Malignancy Consortium
UNC Lineberger Comprehensive Cancer Center
NRG Oncology
Imugene Limited
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Dana-Farber Cancer Institute
ImmunityBio, Inc.
Bruckner Oncology
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Tyme, Inc
Merck Sharp & Dohme LLC
Asan Medical Center
Merck Sharp & Dohme LLC
Taiho Oncology, Inc.
University of Cincinnati
BioLineRx, Ltd.
ImmunityBio, Inc.
AIDS Malignancy Consortium
Bristol-Myers Squibb
ImmunityBio, Inc.
National Cancer Institute (NCI)
ImmunityBio, Inc.
Academic and Community Cancer Research United
Ludwig Institute for Cancer Research